Lifelight(R) Junior: a contactless early infection detection tool for clinically vulnerable children

总部位于南安普敦的中小企业“xim”正在开发Lifelight（R）Junior，这是一种仅用智能手机摄像头就能测量儿童心率、呼吸频率、血压和血氧饱和度，并在40秒内检测发烧的技术。新冠肺炎疫情凸显了体育活动、社交和教育对所有儿童的智力、社交和身体发展的重要性。尽管如此，父母仍然普遍限制临床脆弱儿童的活动，以尽量减少接触任何感染。其他父母不限制活动，但生活在高度焦虑中。对临床上易受感染的儿童进行频繁的生命体征监测可以让父母放心，如果他们的孩子确实感染了病毒，可以在严重恶化之前发现。这可能会让他们更有信心让他们的孩子参与日常的儿童活动，这是他们的医疗团队为大多数这些孩子推荐的。Lifelight（r）Junior让那些希望在孩子感染早期症状时得到提醒的父母放心，为临床脆弱儿童的心理，身体，社会和教育需求提供了一种风险衡量方法，以更大程度地满足。这是因为它的非接触式特性和在日常智能手机技术上操作的能力使得定期的生命体征监测变得毫不费力。对于那些觉得血压袖带和温度计等传统设备令人苦恼或不方便的人来说，它尤其有用。这个为期24个月的项目的目的是利用从xim过去三次临床试验中收集的数据，构建、训练和测试Lifelight（R）Junior（VISION D，VISION Acute和VISION MD），它们总共收集了超过20，000个训练数据集。Lifelight（r）Junior是xim开发的第二个解决方案。Lifelight（r）First是xim的第一个解决方案-一种非接触式CE认证的工具，用于测量18岁及以上成年人的心率，呼吸率和血压。Xim此前已赢得500万英镑以上的资金用于Lifelight（r）First的研发：\*SBRI -第一阶段和第二阶段\*Innovate UK- Smart Award，A4 I，Innovation Loan\*NIHR - AI in Health and Care Award\*SIGHT\*KEEP+Lifelight（r）在2020年MedTech Awards中被评为“最前沿的血压监测解决方案”，2021年获得NICE的Med Tech Innovation Briefing，被mHealth杂志评为“全球数字健康100强”公司，并被Wessex AHSN的2020年和2021年年度评论所收录。

Southampton-based SME "xim" is developing Lifelight(R) Junior, a technology that can measure a child's heart rate, respiratory rate, blood pressure and oxygen saturation and detect fever in just 40 seconds using only a smartphone camera.The COVID-19 pandemic has highlighted the importance of physical activity, socialisation and education on the mental, social and physical development of all children. Nevertheless, it remains common for parents to restrict the activities of clinically vulnerable children to minimise exposure to any infection. The result is lower academic attainment, higher rates of social isolation and mental illness, etc. Other parents do not restrict activities but live with heightened anxiety.Frequent vital sign monitoring of clinically vulnerable children can reassure parents that if their child does contract infection, it can be detected before significant deterioration occurs. This may make them more confident to allow their children to engage in everyday childhood activities, as is recommended for most of these children by their healthcare teams.Lifelight(r) Junior brings peace of mind to parents who wish to be alerted to early signs of infection in their children, providing a risk-measured way for the mental, physical, social and educational needs of clinically vulnerable children to be more greatly met. This is because its contactless nature and ability to operate on everyday smartphone technology makes regular vital sign monitoring effortless. It is particularly useful for those who find traditional equipment, such as blood pressure cuffs and thermometers, distressing or inconvenient.The aim of this 24-month project is to build, train and test Lifelight(R) Junior using data collected from xim's three past clinical trials (VISION D, VISION Acute and VISION MD) which together collected more than 20,000 training datasets.Lifelight(r) Junior is the second solution to be developed by xim. Lifelight(r) First is xim's first solution - a contactless, CE-marked tool that measures heart rate, respiratory rate and blood pressure in adults aged 18 years and above.Xim has previously won £5M+ to fund Lifelight(r) First R&D:\*SBRI - Phase 1 and Phase 2\*Innovate UK -- Smart Award, A4I, Innovation Loan\*NIHR -- AI in Health and Care Award\*SIGHT\*KEEP+Lifelight(r) has been named the "Most Cutting-Edge Blood Pressure Monitoring Solution" in the 2020 MedTech Awards, received a Med Tech Innovation Briefing from NICE in 2021, appointed a "Global Digital Health 100" company by mHealth journal, and was featured in Wessex AHSN's 2020 & 2021 Annual Reviews.